Immutep Limited

DB:YP1B Stock Report

Market Cap: €296.4m

Immutep Management

Management criteria checks 3/4

Immutep's CEO is Marc Voigt, appointed in Nov 2012, has a tenure of 12.08 years. total yearly compensation is A$1.06M, comprised of 44.8% salary and 55.2% bonuses, including company stock and options. directly owns 0.77% of the company’s shares, worth €2.28M. The average tenure of the management team and the board of directors is 7 years and 2.6 years respectively.

Key information

Marc Voigt

Chief executive officer

AU$1.1m

Total compensation

CEO salary percentage44.8%
CEO tenure12.1yrs
CEO ownership0.8%
Management average tenure7yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Marc Voigt's remuneration changed compared to Immutep's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$477k

-AU$43m

Mar 31 2024n/an/a

-AU$42m

Dec 31 2023n/an/a

-AU$41m

Sep 30 2023n/an/a

-AU$40m

Jun 30 2023AU$1mAU$440k

-AU$40m

Mar 31 2023n/an/a

-AU$38m

Dec 31 2022n/an/a

-AU$37m

Sep 30 2022n/an/a

-AU$34m

Jun 30 2022AU$943kAU$428k

-AU$32m

Mar 31 2022n/an/a

-AU$29m

Dec 31 2021n/an/a

-AU$26m

Sep 30 2021n/an/a

-AU$28m

Jun 30 2021AU$995kAU$409k

-AU$30m

Mar 31 2021n/an/a

-AU$29m

Dec 31 2020n/an/a

-AU$27m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$926kAU$411k

-AU$13m

Mar 31 2020n/an/a

-AU$15m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$17m

Jun 30 2019AU$837kAU$399k

-AU$18m

Mar 31 2019n/an/a

-AU$18m

Dec 31 2018n/an/a

-AU$17m

Sep 30 2018n/an/a

-AU$15m

Jun 30 2018AU$1mAU$401k

-AU$13m

Compensation vs Market: Marc's total compensation ($USD665.88K) is below average for companies of similar size in the German market ($USD1.01M).

Compensation vs Earnings: Marc's compensation has been consistent with company performance over the past year.

CEO

Marc Voigt (51 yo)

12.1yrs

Tenure

AU$1,064,669

Compensation

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

Leadership Team

NamePositionTenureCompensationOwnership
Marc Voigt
CEO, MD12.1yrsAU$1.06m0.77%
€ 2.3m
Deanne Miller
COO, General Counsel & Joint Company Secretary12.2yrsAU$565.23k0.18%
€ 543.6k
Frederic Triebel
Chief Scientific Officer & Executive Director10yrsAU$864.44k0.61%
€ 1.8m
Florian Vogl
Chief Medical Officer1.6yrsAU$955.82kno data
Christian Mueller
Senior Vice President of Regulatory & Strategy1.2yrsno datano data
Indira Naidu
Joint Company Secretary3.9yrsno datano data

7.0yrs

Average Tenure

51yo

Average Age

Experienced Management: YP1B's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc Voigt
CEO, MD10.4yrsAU$1.06m0.77%
€ 2.3m
Frederic Triebel
Chief Scientific Officer & Executive Director2.3yrsAU$864.44k0.61%
€ 1.8m
Russell Howard
Independent Non-Executive Chairman11.6yrsAU$163.52k0.097%
€ 289.0k
Pete Meyers
Independent Non-Executive Deputy Chairman10.8yrsAU$138.71k0.25%
€ 746.6k
Martine Piccart
Chairman of Clinical Advisory Board7.5yrsno datano data
Scott Antonia
Member of Clinical Advisory Board2.6yrsno datano data
Leisha Emens
Member of Clinical Advisory Board2.6yrsno datano data
Elisabeth Boyce
Non-Executive Director1.7yrsAU$144.76k0.018%
€ 52.3k
Salah-Eddin Al-Batran
Member of Clinical Advisory Board7.5yrsno datano data
Martin Forster
Member of Clinical Advisory Board2.6yrsno datano data
Hans Wildiers
Member of Clinical Advisory Board2.6yrsno datano data

2.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: YP1B's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:32
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immutep Limited is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Thomas WakimBell Potter
Tara SperanzaBell Potter